A Seminal Moment for Life Sciences
In this PharmaVOICE article, Saama’s Chief Strategy Officer Sagar Anisingaraju explains why sponsors and CROs that fail to adopt a technology transformation strategy for drug development will fall behind in the post-pandemic era.
With the accelerated adoption of AI-powered technology solutions over the past two years, fast-tracking novel therapies is now the norm, not the exception.
“The global pandemic forced our industry to abandon passive acceptance of the decade-long timeline that had been the standard for bringing new drugs to market”
The article highlights how AI-based technology solutions help drug developers connect, contextualize, and converse with clinical trial data. It’s a must read for key stakeholders from the front end of the research and development process to the back end of putting new therapies in the hands of healthcare professionals and patients.
